NEWS

![]() Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL). Mar 3, 2022![]() AASLD Poster: Comparing Non-Invasive Tools – LIVERFASt™, FIB-4 and Transient Elastography in Sequential and Combinatory Pathways for NAFLD. Aug 7, 2021![]() AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods. Aug 7, 2021 |
![]() ADA 2021: LIVERFAStTM Has Similar Performance to Liver Biopsy for the Screening of NASH Fibrosis in Type 2 Diabetes Mellitus (T2D). Jun 26, 2021![]() EASL Poster: Noninvasive LIVERFASt transition rate to liver fibrosis is similar to that estimated with liver biopsy in NAFLD patients. Jun 23, 2021![]() Fibronostics and Fatty Liver Foundation Announce a Patient Education Partnership Dec 07, 2020 |
![]() Fibronostics US INC, receives CE (Conformité Européenne) mark approval for the product LIVERFASt™ ![]() AASLD Poster: LIVERFASt is detecting and discriminant different phases of liver disease, with better performances than APRI or FIB-4. Nov 25, 2020 |
![]() AASLD Poster: Comparative performance of LIVERFASt™, Fibroscan and other non-invasive test for Severe Fibrosis in NAFLD Patients. Nov 21, 2020![]() LIVERFASt™ provides the right diagnosis of liver disease conditions in type 2 diabetes patients. Nov 01, 2020 |
![]() Fibronostics on its way to be a Healthcare Technology Powerhouse – Raises $8 Million Series A funding. Aug 24, 2020![]() Fibronostic’s Chief Scientific Officer,Dr Mona Munteanu, discussed relevance of Non-Invasive Testing for HCC Surveillance in global Webinar series. Aug 21, 2020![]() Know the advantages of non-invasive liver diagnostics over standard biopsy as explained by our CEO, Roni Amiel. Aug 21, 2020 |
![]() Fibronostics presented a Scientific poster “Assessment of fatty liver disease using a biomarker-based non-invasive algorithm LIVERFASt™ test in South-East Asia”.at the NASH-TAG 2020, UTAH for. Aug 21, 2020![]() Celebrating a major milestone! Fibronostics granted CPT code for LIVERFASt, our non-invasive liver diagnostics tool. Aug 05, 2020![]() When things go tough due to flight restrictions, we conduct our CMEs through video conferences by our Chief Medical Officer, Dr Ronald Quiambao. Jun 08, 2020 |
![]() Fibronostics is proud to partner with the CXA Group offering health and wellness screenings with HealthFACTR. Dec 13, 2019![]() Fibronostics mingles with industry leaders during inspiring few days at the American Association for the Study of Liver Diseases (AASLD) #LiverMtg19. Nov 07, 2019![]() AC Health announces Investment in Fibronostics by launching LIVERFASt and HealthFACTR in its FamilyDOC Clinics. Jul 06, 2019 |
![]() Fibronostics presented our corporate strategy to current & potential investors in TKS 1 Investor Day in Singapore. Feb 27, 2019 |